Abbott Gains on Medtronic in LVAD Market

Abbott Laboratories said late-breaking clinical trial data from its MOMENTUM 3 clinical study shows its HeartMate 3 Left Ventricular Assist Device (LVAD) has improved survival and lowered rates of stroke and pump thrombosis. The Abbott Park, IL-based company released the data during the American College of Cardiology’s 67th Annual Scientific Sessions this past weekend. Data from MOMENTUM 3 was also published in the New England Journal of Medicine and showed patients with the HeartMate 3 LVAD had a survival rate of 82.8% at two years compared with 76.2% for those with the HeartMate II LVAD. Pump thrombosis rates remained very low, at 1.2% suspected thrombosis for the HeartMate 3 LVAD with no reoperations, pump replacements or urgent transplants occurring at two years. Stroke rate was significantly lower (10% ) for the HeartMate 3 LVAD compared with the HeartMate II LVAD (19%). Join us at the BIOMEDevice Boston Expo, April 18–19, 2018. Use promo code "MDDI" for 20% off conference registration and free expo access. The MOMENTUM 3 study data, which will be submitted to FDA to support consideration of a long-term (destination therapy) indication for Abbott's HeartMate 3 LVAD, compared the HeartMate 3 LVAD to the HeartMate II LVAD in treating advanced heart failure. “Abbott’s MOMENTUM 3 trial demonstrated the superiority of the company’s HeartMate 3 left ventricular assist device vs. HeartMate 2 at two years, setting a fairly clear pathway for U.S. destination therapy ap...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Cardiovascular Source Type: news